NeoPharm (NEOL) Posts Q3 Loss of $0.06
More News related to NEOL
- NeoPharm Presents the Phase I Data for Patients with Metastatic Solid Tumors
- NeoPharm Names Dr. Aquilur Rahman as President and CEO
- NeoPharm Submits Application for a Multicenter, Open-Label, Phase II Study of LE-DT for Locally Advanced or Metastatic Pancreatic Cancer Patients as a Frontline Treatment
- NeoPharm (NEOL) Posts Q3 Loss of $0.06
- NeoPharm, Inc. Announces Third Quarter 2009 Financial Results and Clinical Trials Update
NeoPharm, Inc. (NASDAQ: NEOL) reports Q3 loss of $0.06, compared to ($0.08) in the same quarter last year.
Related Categories
EarningsStocks Mentioned
-0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
